Acrongenomics, Inc. Retains KGMC Group, LLC
Released on = November 16, 2005, 9:45 am
Press Release Author = Acrongenomics Inc.
Industry = Biotech
Press Release Summary = FRANKFORT, Ill.--(BUSINESS WIRE)--Nov. 8,
2005--Acrongenomics, Inc. (OTCBB:AGNM - News) is pleased to announce that it has
retained KGMC Group, LLC of Frankfort, Illinois to introduce its cutting-edge
Nano-JETA(TM) technology platform to the world market.
Press Release Body = Privately-held KGMC Group LLC (www.kgmcgroup.com) introduces
and markets advanced medical technologies. With a diverse team of talented and
respected professionals in medicine, science, business, finance, marketing and law
from four continents, KGMC provides services and solutions essential to converting
emerging technologies into viable business ventures. KGMC Group LLC will work with
Acrongenomics to complete formal validations of the advanced Nano-JETA(TM) platform,
secure publications of this breakthrough technology in respected medical and
scientific journals and identify ideal partners to commercialize the technology.
"Following a year of thorough study, our scientists and Board of Directors have
confirmed that Acrongenomics' know-how in nanotechnology has resulted in compelling
breakthroughs, significantly impacting our battle with various diseases such as
cancer. We are convinced that Nano-JETA(TM) technology platform can accelerate and
enhance the commonly used Real Time PCR amplification process, so that it is
rendered 100% accurate in detecting genetic diseases such as cancer. Neo-EpCAM(TM)
cancer detection assay is the first application utilizing the Nano-JETA(TM)
technology. More so exciting is that the process takes less than two minutes.
Because it is fast, inexpensive, easy to administer, non-invasive, accurate,
specific and uses existing equipment, we are convinced that the technology will
assist physicians in detecting genetic diseases quickly, accurately and early enough
to potentially save lives and avoid much cost and anguish. Now confident in the
technology, we will assist Acrongenomics in securing a partner to further develop and market such technology," Says
KGMC Group President Bill Kanatas.
Acrongenomics Inc. (www.acrongen.com) (OTCBB:AGNM - News) is a publicly traded
research and development nanobiotechnology company pioneering the development of
uniquely advanced nano-molecular diagnostics for the Life Sciences Industry. The
Company is seeking to establish its proprietary nanotechnology platform as a global
standard in Molecular In Vitro Diagnostics.
Acrongenomics has successfully conducted laboratory tests and clinical trials for
the cancer detection and quantification process. The technology has been applied to
major Molecular Diagnostics techniques such as Polymerase Chain Reaction (PCR) and
Real-Time PCR producing outstanding results in terms of sensitivity,
reproducibility, specificity and speed with the use of conventional equipment.
Since the completion of the Human Genome project in 2000, the growing number of
sequencing and functional genomic initiatives has resulted in the rapid growth of
the Molecular Diagnostics field. In 2005, the global market for molecular
diagnostics is estimated to reach $6.5 billion. By 2010 the market is forecasted to
expand to $12 billion and to $35 billion by 2015 (Research & Markets Report 2004).
There is considerable demand for new molecular diagnostic technologies. So
profitable is the molecular diagnostics market that pharmaceutical and biotechnology
companies are highly focused in developing molecular diagnostics tests that can be
used to individualize patient treatments.
With the validation and introduction of the Nano-JETA(TM) technology platform, along
with the support of KGMC Group LLC, Acrongenomics is positioned to emerge as a
leader in this rapidly expanding market segment.
Web Site = http://www.acrongen.com
Contact Details = Tom Skarpelos
Investor Relations
38A Posidonos Avenue
17455 Alimos
Athens, Greece
info@acrongen.com
+30 2109859203
Printer
Friendly Format
Back
to previous page...
Back
to home page...
Submit
your press releases...
|
2012
